| Disease | Tissue/ Cell line | MicroRNA regulation | Targeted Member | Pathway | More Details | References |
|---|---|---|---|---|---|---|
| Parkinson's disease | HEK293 | Up | NMDAR2 | Neuroactive ligand-receptor interaction pathway | MicroRNA-137 directly regulates Neuroactive ligand-receptor interaction pathway through downregulating NMDAR2. | Kong et al., 2015 |
| Parkinson's disease | HEK293 | Up | D2R | Neuroactive ligand-receptor interaction pathway | MicroRNA-137 directly regulates Neuroactive ligand-receptor interaction pathway through downregulating D2R. | Kong et al., 2015 |
| Parkinson's disease | HEK293 | Up | GABA B R3 | Neuroactive ligand-receptor interaction pathway | MicroRNA-137 directly regulates Neuroactive ligand-receptor interaction pathway through downregulating GABA-B-R3. | Kong et al., 2015 |
| Gastric cancer | Gastric cancer tissue | Down | CUL4A | Hippo signaling pathway | Upregulation of miR-137 inhibits the CUL4A-LATS1-Hippo signaling pathway and represses gastric cancer cell proliferation and invasion. | Deng et al., 2016 |
| Gastric cancer | MGC-803, HGC-27, MKN-45,SGC-7901 | Down | COX 2 | PI3K-Akt signaling pathway | MicroRNA-137 acts as a tumor suppressor through suppressing Cyclooxygenase-2 (Cox-2), which inhibits the activation of PI3K-Akt signaling pathway. | Cheng et al., 2014 |
| Hepatocellular carcinoma | Hepatocyte | Down | AKT | mTOR pathway | FoxD3-regulated miR-137 suppresses hepatocellular carcinoma cell growth and metastasis through inhibiting AKT2/mTOR pathway via targeting AKT2. | Liu et al., 2014 |